Twinbeech Capital LP bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 279,944 shares of the company's stock, valued at approximately $22,916,000. Twinbeech Capital LP owned approximately 0.22% of Vaxcyte at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Toronto Dominion Bank purchased a new position in shares of Vaxcyte during the 4th quarter valued at approximately $900,000. Scientech Research LLC lifted its position in shares of Vaxcyte by 18.5% during the 4th quarter. Scientech Research LLC now owns 15,273 shares of the company's stock valued at $1,250,000 after buying an additional 2,385 shares in the last quarter. Rafferty Asset Management LLC lifted its position in shares of Vaxcyte by 128.6% during the 4th quarter. Rafferty Asset Management LLC now owns 147,436 shares of the company's stock valued at $12,069,000 after buying an additional 82,940 shares in the last quarter. ProShare Advisors LLC lifted its position in shares of Vaxcyte by 40.2% during the 4th quarter. ProShare Advisors LLC now owns 40,875 shares of the company's stock valued at $3,346,000 after buying an additional 11,729 shares in the last quarter. Finally, Paradigm Biocapital Advisors LP lifted its position in shares of Vaxcyte by 57.3% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,422,787 shares of the company's stock valued at $116,469,000 after buying an additional 518,255 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.
Insiders Place Their Bets
In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the firm's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the completion of the sale, the chief operating officer now directly owns 154,931 shares of the company's stock, valued at $11,351,794.37. This trade represents a 4.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 3.10% of the company's stock.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on PCVX. Bank of America decreased their target price on Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. The Goldman Sachs Group decreased their target price on Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Needham & Company LLC reiterated a "buy" rating and set a $90.00 target price on shares of Vaxcyte in a research report on Tuesday, April 8th. Guggenheim reissued a "buy" rating and issued a $160.00 price objective on shares of Vaxcyte in a research note on Wednesday, March 12th. Finally, Evercore ISI raised Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. Nine equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $136.50.
Get Our Latest Stock Analysis on Vaxcyte
Vaxcyte Price Performance
NASDAQ PCVX traded down $1.41 during mid-day trading on Friday, hitting $32.54. The stock had a trading volume of 1,763,863 shares, compared to its average volume of 1,367,883. The firm's 50 day moving average is $38.53 and its 200 day moving average is $69.43. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06. The stock has a market capitalization of $4.20 billion, a price-to-earnings ratio of -7.07 and a beta of 1.27.
Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter in the previous year, the business earned ($0.85) earnings per share. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.
About Vaxcyte
(
Free Report)
Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.
Read More
Before you consider Vaxcyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vaxcyte wasn't on the list.
While Vaxcyte currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
